Holen Sie sich die Stockscreener-App
2.3601
1.29%
0.0301
Schlusskurs vom Vortag:
$2.33
Offen:
$2.36
24-Stunden-Volumen:
804.40K
Relative Volume:
0.41
Marktkapitalisierung:
$401.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.18M
KGV:
-0.9312
EPS:
-2.5346
Netto-Cashflow:
$-198.33M
1W Leistung:
+42.17%
1M Leistung:
+13.73%
6M Leistung:
+131.37%
1J Leistung:
-0.42%
1-Tages-Spanne:
$2.295
$2.57
1-Wochen-Bereich:
$1.50
$2.57
52-Wochen-Spanne:
$0.611
$3.25
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Vergleichen Sie NMRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.36 | 395.96M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.00 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.42 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.45 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.41 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-09-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Is Neumora Therapeutics Inc. stock a defensive play in 2025Gap Down & Advanced Technical Analysis Signals - ulpravda.ru
Investment Review: Why Neumora Therapeutics Inc. stock could rally in 2025Quarterly Market Review & High Accuracy Swing Trade Signals - ulpravda.ru
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
Trend Review: What hedge fund activity signals for Neumora Therapeutics Inc. stockJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - ulpravda.ru
Mizuho reiterates Outperform rating on Neumora Therapeutics stock By Investing.com - Investing.com Canada
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), DENTSPLY SIRONA (XRAY) - The Globe and Mail
Neumora outlines 2026 pipeline milestones for neuroscience programs By Investing.com - Investing.com Nigeria
Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target - TipRanks
Mizuho raises Neumora Therapeutics stock price target on positive trial data - Investing.com Canada
Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer’s agitation, eyes higher doses - MarketBeat
Neumora shares climb after encouraging Phase 1b results for Alzheimer’s agitation therapy - MSN
Why Is Neumora Therapeutics Stock Gaining Monday?Neumora Therapeutics (NASDAQ:NMRA) - Benzinga
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug - Investing.com Canada
NMRA Surges On Clinically Meaningful Results In Phase 1 Alzheimer's Disease Agitation Study - Nasdaq
Neumora outlines 2026 pipeline milestones for neuroscience programs - Investing.com
Neumora posts trial results for Alzheimer’s drug (NMRA:NASDAQ) - Seeking Alpha
Neumora reports promising Phase 1b results in Alzheimer’s agitation - TipRanks
Neumora Therapeutics Announces Positive Phase 1b Study Results for NMRA-511 - TradingView — Track All Markets
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - The Manila Times
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation - The Manila Times
New Alzheimer’s treatment candidate eases agitation in early study - Stock Titan
10 Best New Penny Stocks to Invest In - Insider Monkey
RBC Sees Upside Potential in Neumora Therapeutics (NMRA) - Finviz
What analysts say about Neumora Therapeutics Inc stockMid Cap Growth Trends & Free Superior Trading Gains - earlytimes.in
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug By Investing.com - Investing.com Canada
Momentum Shift: Will Neumora Therapeutics Inc. stock benefit from AI adoptionNew Guidance & Consistent Income Trade Recommendations - moha.gov.vn
Cash Runway Looks Solid, But Is Neumora's Pipeline Ready To Deliver? - RTTNews
Is Neumora Therapeutics Inc. stock resilient to inflation2025 Volatility Report & Fast Gaining Stock Reports - Улправда
Can Neumora Therapeutics Inc. stock beat market expectations this quarterQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда
Analyst Calls: How Neumora Therapeutics Inc stock reacts to job market dataIPO Watch & Smart Swing Trading Techniques - moha.gov.vn
Will Neumora Therapeutics Inc. stock beat EPS estimates2025 EndofYear Setup & Risk Controlled Stock Pick Alerts - DonanımHaber
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Neumora Therapeutics Earnings Notes - Trefis
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
MACD Signal: Can Neumora Therapeutics Inc stock beat market expectations this quarterJuly 2025 Update & Verified Chart Pattern Signals - BỘ NỘI VỤ
Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital - MSN
Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset - MSN
Can Neumora Therapeutics Inc. stock weather global recession2025 Price Action Summary & Free Long-Term Investment Growth Plans - Newser
How Neumora Therapeutics Inc. stock reacts to job market dataQuarterly Trade Review & Free Accurate Trade Setup Notifications - Newser
Is Neumora Therapeutics Inc. stock attractive for ETFsPortfolio Growth Summary & Technical Buy Zone Confirmation - Newser
What momentum indicators show for Neumora Therapeutics Inc. stockGold Moves & Safe Capital Investment Plans - Newser
Neumora Therapeutics (NMRA) Stock Analysis Report | Financials & Insights - Benzinga
Neumora Therapeutics stock rating upgraded by RBC Capital on NLRP3 potential - Investing.com Canada
Neumora Therapeutics Shares Rise After RBC Upgrade - marketscreener.com
Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset (NMRA:NASDAQ) - Seeking Alpha
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):